Alibaba Health's performance for the full year ended at the end of March was better than expected, and revenue trends in all major business segments were stable.
Bank of America Securities released a research report stating that it will maintain$ALI HEALTH (00241.HK)$A “buy” rating, with a target price of HK$4.5, and is expected to show good business momentum in the 2025 fiscal year. It is expected that revenue will resume positive growth, profit growth will accelerate, and benefit from the integration of newly acquired high-profit marketing businesses.
According to the report, the company's performance for the full year ended at the end of March was better than expected, and the revenue trends in all major business segments were stable. Due to operating cost control and efficiency improvements, net profit for the 2024 fiscal year was 883 million yuan, far higher than the bank's expectations. Gross profit increased 3% year over year, in line with expectations.